Cantor Fitzgerald Maintains Overweight on InflaRx, Raises Price Target to $6

Benzinga · 1d ago
Cantor Fitzgerald analyst Steve Seedhouse maintains InflaRx (NASDAQ:IFRX) with a Overweight and raises the price target from $4 to $6.